FDA Confirms Single Pivotal Trial Pathway for Elate Ocular
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Cambium Bio Ltd announces that the FDA has confirmed a single pivotal trial pathway for its Elate Ocular product, which is aimed at treating moderate-to-severe dry eye disease. This new pathway significantly reduces development costs and accelerates the timeline for submitting a Biologics License Application.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Cambium Bio
- Half Year Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- Cambium Bio Secures A$2.4 Million Strategic Investment
- Cambium Bio Signs Strategic MoU with Benta SAS
- Cambium Bio Signs US$2.0M plus Licensing Deal
Later from Cambium Bio
- Cambium Bio Raises A$1.0 Million via Placement
- Updated Securities Trading Policy
- Change in Company Secretary and Communication Person
- FY26 Appendix 4G and Corporate Governance Statement
- FY26 Appendix 4E and Annual Report
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio